PDLI PDL BioPharma, Inc.

2.46-0.07 (-2.77%)
Close: August 23, 2019

Quote

Previous Close
$2.46
Day Range
$2.44-$2.54
52 Week Range
$2.25-$3.89
Volume
1,696,802
Avg Volume
1,130,854
Dividend TTM
-
Ex-Dividend Date
2016-06-02

Valuation

Market Cap
$280.94M
Enterprise Value (EV)
$18.99M
PE Ratio
7.98
EV/EBITDA
0.23
Price/Sales
1.46
Price/Book
0.38
PEG Ratio
-

Financials

Revenue
$198.11M
Gross Profit
$133.82M
EBITDA
$84.14M
EPS, ttm
$0.31
Profit Margin
-
Revenue/Employee
$1.89M
Next Earnings Date
11/6/2019 (73 days)
Debt to Equity
17%
Debt
$132.64M
Cash
$394.59M
Net Debt
-

Performance

Beta
1.21
200 Day Moving Avg
$3.16
50 Day Moving Avg
$2.94
52 Week Change
5.13%
YTD Change
-18.23%
1 Month Change
-21.41%
3 Month Change
-16.89%
6 Month Change
-33.33%
1 Year Change
5.13%
2 Year Change
52.70%
5 Year Change
-59.69%

Share Count

Shares Outstanding
114.2M
Float
111.2M
Restricted Shares
3.0M
Restricted Shares, %
2.67%

PDL BioPharma, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Dominique Monnet

Website: http://www.pdl.com

Description: PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.

Employees: 105